WHO experts recommend two Bundibugyo vaccine candidates for the trial in DR Congo

Colorized archival transmission electron micrograph of an Ebola virus particle, not a specimen from the current Bundibugyo virus trial or a photograph of a vaccine. Source: CDC/Cynthia Goldsmith, PHIL 10816, available free of charge from the CDC website; US federal-government public-domain work and conditions of use. Use of this image does not imply endorsement of this website by CDC, HHS or the US government.

An expert recommendation is not marketing approval

The candidate vaccine prioritization group convened by the World Health Organization has recommended adding ChAdOx1 BDBV, developed by a University of Oxford-linked team, and Moderna's mRNA-1469 to the ongoing Tumaini phase II/III clinical trial in the Democratic Republic of the Congo. The group's most recent meeting took place on November 2, 2026; the recommendations and news release were published on November 4. WHO says the two candidates were designed against Bundibugyo virus, the virus involved in the current outbreak. Their entry into the trial remains subject to national approval. This is a research recommendation, not regulatory approval for marketing or proof that the vaccines work.¹²³

Ring vaccination cannot presume cross-virus protection

Tumaini uses a ring-vaccination research design, establishing vaccination rings around contacts of confirmed cases to compare candidates' protective effects during the outbreak response. WHO says four rings have already been initiated, with more in preparation. The existing Ervebo vaccine previously established efficacy against a different type of Ebola virus, Zaire ebolavirus. In this trial it is being evaluated against Bundibugyo virus; cross-virus protection cannot be assumed.¹

Early evidence supports research, not an efficacy conclusion

The official overview of the expert group's report lists the evidence reviewed, including preclinical studies, early safety and immunogenicity findings, manufacturing and available doses. Early safety or immune-response data may support proceeding to the next stage of research, but cannot replace protective-efficacy data from the outbreak setting. WHO expects vaccine trial results in early 2027. Treatment research is also under way, but its outcomes likewise remain uncertain.¹²

Approvals and field implementation determine the next steps

The importance of this development is that research tools targeting a specific pathogen are being advanced toward testing in an outbreak, not that a vaccine has already succeeded. Whether the trial can proceed on schedule depends on approvals, supply, enrolment of contacts and field implementation. Those milestones, efficacy results and safety results need to be followed separately, without treating a candidate product, permission to enter a trial and a vaccine formally available for use as the same thing.¹²

Source notes

1. 2026-11-04 · Two new candidate vaccines to join Ebola trial as treatment research advances · World Health Organization. ↩ ↩² ↩³ ↩⁴

2. 2026-11-04 · Fourth, fifth, sixth and seventh meetings of the WHO Technical Advisory Group on candidate vaccine prioritization (TAG–CVP) for Bundibugyo virus disease outbreak response: Meeting report, 1 September, 19 October, 22 October and 2 November 2026 · World Health Organization. ↩ ↩² ↩³

3. 2026-10-23 · First participant vaccinated in pivotal Phase 2/3 Bundibugyo vaccine trial in DRC · Institute of Tropical Medicine. ↩